Table 1.
Variables in the study population according to QFT-TB test results.
| QFT + (n=7) | QFT – (n=53) | p | ||
|---|---|---|---|---|
| Age | Median (range) | 61 (50–83) | 64 (18–83) | 0.3 |
| Sex | Male, n (%) | 3 (43) | 31 (58) | 0.6 |
| Female, n (%) | 4 (57) | 22 (42) | ||
| Foreign born | n (%) | 1 (14) | 6 (11) | 0.9 |
| Smoking habit | n (%) | 4 (57) | 22 (42) | 0.4 |
| Diagnosis | AML, n (%) | 6 (86) | 40 (75) | 0.7 |
| ALL ph+, n (%) | 0 | 3 (6) | ||
| ALL, ph−, n (%) | 1 (14) | 7 (13) | ||
| APL, n (%) | 0 | 3 (6) | ||
| Intensive treatment * | n (%) | 4 (57) | 29 (55) | 0.9 |
| Treatment phase | Induction, n (%) | 6 (86) | 50 (95) | 0.6 |
| Consolidation, n (%) | 1 (14) | 3 (5) | ||
| Neutrophils ** (x10 9 /L) | Median (range) | 0,950 (0,32–3,44) | 650 (20–23.600) | 0.5 |
| Lymphocytes ** (x10 9 /L) | Median (range) | 1,48 (0,74–7,43) | 0,92 (0,16–145,75) | 0.2 |
| Monocytes ** (x10 9 /L) | Median (range) | 0,88 (0,25–5,62) | 0,20 (0–51,07) | 0.1 |
| Bronchoalveolar lavage (BAL) positivity *** | n (%) | 2 (40) | 4 (7) | 0.1 |
| Not performed, n (%) | 2 (28.5) | 25 (47) | ||
| Pulmonary lesion at RX | n (%) | 6 (86) | 23 (42) | 0.2 |
| Not detected, n (%) | 4 (57) | 32 (58) | ||
| Pneumonia of other origin | n (%) | 4 (57) | 25 (47) | 0.8 |
| Comorbidities | HIV infection, n (%) | 0 (0) | 0 (0) | |
| Diabetes, n (%) | 1 (14) | 5 (9) | ||
| COPD, n (%) | 0 (0) | 0 (0) | ||
| Previous cancer, n (%) | 0 (0) | 5 (9) |
Two patients (in the Quantiferon – group) were tested in an off-treatment setting (post-transplant).
A blood test was performed at Quantiferon’s time.
BAL was performed to investigate the direct or indirect presence of bacterial or fungal infection. The 2 Quantiferon + patients were also positive for Pneumocystis jirovecii and Enterococcus faecalis in BAL. Among the 3 Quantiferon – patients, one resulted positive for Pneumocystis jirovecii, one for Enterobacter kobei, and two for Galactomannan.
Abbreviations: AML, Acute Myeloid Leukemia; ALL, Acute Lymphoblastic Leukemia; APL, Acute Promyelocytic Leukemia; QFT, QuantiFERON-TB test; HIV, Human Immunodeficiency Virus; COPD, Chronic Obstructive Pulmonary Disease.